{"id":10293,"date":"2020-11-09T13:16:45","date_gmt":"2020-11-09T04:16:45","guid":{"rendered":"https:\/\/symdfmtcopro.wpenginepowered.com\/post\/10293"},"modified":"2024-01-11T15:21:49","modified_gmt":"2024-01-11T06:21:49","slug":"efforts-of-our-study-groups-stool-bank-japanbiome-on-new-coronaviruses","status":"publish","type":"post","link":"https:\/\/fmt-japan.org\/en\/post\/10293","title":{"rendered":"Efforts of our study group’s stool bank Japanbiome on new coronaviruses"},"content":{"rendered":"\r\n
\"\"<\/figure>\r\n\r\n\r\n\r\n

The Intestinal Flora Transplant Clinical Research Foundation and Japanbiome (Intestinal Flora Transplant Donor Bank) are working to ensure that patients who wish to receive an intestinal flora transplant can do so with peace of mind.
The number of patients who wish to undergo intestinal flora transplantation has been increasing as academic reports recognizing the usefulness of intestinal flora transplantation for various intestinal diseases such as ulcerative colitis, allergies, and autism spectrum disorders, including the application for multi-drug-resistant Clostridioides difficile infection recommended by the FDA, a US government agency, have been published around the world one after another. The number of patients who wish to undergo intestinal flora transplantation is increasing.<\/p>\r\n\r\n\r\n\r\n

Amid global efforts to prevent the spread of the new coronavirus, Japanbiome has temporarily suspended the donation of stools from all donors and has been manufacturing transplantation solution only from stools donated by December 31, 2019.
We are pleased to announce that we will resume the donation and use of donor stools for transplantation solution at the end of 2019. In order to do so, we have reviewed the criteria for donor selection and the management system for handling transplantation solution as follows.<\/p>\r\n\r\n\r\n\r\n

Although there are currently no reports of novel coronavirus transmission through intestinal flora transplantation (FMT), it is necessary to take the time to carefully assess the risk of infection.
Openbiome, the largest fecal bank in the U.S., is prepared to provide transplants to patients who need them while taking measures to prevent the spread of novel coronaviruses.<\/p>\r\n\r\n\r\n\r\n

Japanbiome has established its own criteria in accordance with the “Guidelines for the Screening of FMT Donors under the Spread of New Coronavirus” by the International Expert Group and with reference to Openbiome’s response, taking into account the differences in circumstances and lifestyle between Japan and the United States and European countries. We have redefined the criteria in accordance with the “Guidelines for screening of FMT donors under the spread of new coronavirus infection.<\/p>\r\n\r\n\r\n\r\n

(Reference: COVID-19 – OpenBiome https:\/\/www.openbiome.org\/covid19<\/a>
Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel – The Lancet Gastroenterology & Hepatology https:\/\/www.thelancet.com\/journals\/langas\/article\/PIIS2468-1253(20)30082-0\/fulltext<\/a>\uff09<\/p>\r\n\r\n\r\n\r\n

<\/span>\u3010Restrictions and new criteria for donors resuming stool donation\u3011<\/span><\/h2>\r\n\r\n\r\n\r\n

Japanbiome conducted antibody testing for novel coronavirus on all donors from June to July 2020, and confirmed that both IgG and IgM were negative. However, the system for testing healthy people and people who are not in close contact with infected people is not yet in place, and considering the burden on donors from frequent blood collection, it is not realistic to conduct frequent testing.<\/p>\r\n\r\n\r\n\r\n

Therefore, in addition to the existing criteria, we have further established the following criteria and have decided to resume stool donation requests only to donors who meet the criteria.<\/p>\r\n\r\n\r\n\r\n